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Because therapeutic manipulation of immunity can induce tumor regression, anti-cancer immunotherapy
is considered a promising treatmentmodality.Wepreviously reported that glypican-3 (GPC3), an oncofetal
antigen overexpressed in hepatocellular carcinoma (HCC), is a useful target for cytotoxic T lymphocyte
(CTL)-mediated cancer immunotherapy, and we have performed clinical trials using the GPC3-derived
peptide vaccine. Although vaccine-induced GPC3-peptide-speciﬁc CTLs were often tumor reactive
in vitro andwere correlatedwith overall survival, no complete responsewas observed. In the current study,
we synthesized liposome-coupledGPC3-derivedCTL epitopepeptide (pGPC3-lipsome) and investigated its
antitumor potential. Vaccinationwith pGPC3-liposome induced peptide-speciﬁc CTLs at a lower dose than
conventional vaccine emulsiﬁed in incomplete Freund's adjuvant. Coupling of pGPC3 to liposomes was
essential for effective priming of GPC3-speciﬁc CTLs. In addition, immunization with pGPC3-liposome
inhibited GPC3-expressing tumor growth. Thus, vaccination with tumor-associated antigen-derived
epitope peptides coupled to the surfaces of liposomes may be a novel therapeutic strategy for cancer.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).3, Glypican-3; HCC, hepato-
e peptide; TAA, tumor-asso-
HC, major histocompatibility
min; pGPC3-liposome, glypi-
57BL/6; A2-Tg mouse, HLA-
e; TAP, transporter-associated
(A2), HLA-A*02:01-restricted
Kb or H2-Db-restricted mu-
hyl sulfoxide; CpG ODN, CpG
-DC, bone marrow-derived
hage colony-stimulating fac-
y; pGPC3(A2)-liposome/CpG,
)-liposome/CpG, pGPC3(B6)-
herapy, Exploratory Oncology
Center, 6-5-1 Kashiwanoha,
; fax: þ81 4 7133 6606.
mmunotherapy, Exploratory
Cancer Center, 6-5-1 Kashi-
7131 5490; fax: þ81 4 7133
ura), tnakatsu@east.ncc.go.jp
r Inc. This is an open access articl1. Introduction
Immunotherapy has become a promising, reﬁned strategy for
tumor treatment [1e5]. Peptide, protein, and DNA vaccines and
antibody therapy have been developed as antigen-speciﬁc immu-
notherapy. Tumor-associated antigens (TAAs) and TAA-derived
peptides recognized by cytotoxic T lymphocytes (CTLs) have been
discovered. We previously identiﬁed glypican-3 (GPC3) as a TAA.
GPC3 is expressed in hepatocellular carcinoma (HCC), melanoma,
and ovary cancer, but not in normal tissues except for the placenta
and embryonic liver [6e8]. Hence, GPC3 is an ideal target molecule
for antigen-speciﬁc cancer immunotherapy.
We previously identiﬁed HLA-A*24:02-restricted GPC3298e306
EYILSLEEL peptide and HLA-A*02:01-restricted GPC3144e152
FVGEFFTDV peptide, and H2-Kb/H2-Db-restricted murine
GPC3127e136 AMFKNNYPSL as CTL epitopes [9e11]. In our clinical
trial, the peptide vaccine was prepared by emulsifying GPC3e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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intradermal injection. However, tumor responses were observed in
a limited number of patients [12e14]. In addition, it has been
recently reported that IFA-based vaccination induces CTL hypo-
responsiveness in mice [15]. Therefore, establishment of a new
vaccine strategy is desired.
Antigen-containing liposome has been attracting interest for
use as a delivery vehicle in new vaccine adjuvants. Antigens
chemically coupled to the liposome surface, which consists of un-
saturated fatty acids, are efﬁciently cross-presented via major his-
tocompatibility complex (MHC) class I by antigen-presenting cells
(APCs) and effectively stimulate antigen-speciﬁc CTLs [16]. Previ-
ously, we reported that peptide-speciﬁc CTLs were induced in mice
immunized with liposome-coupled viral antigen-derived peptide,
protecting the mice from viral infection [17]. Furthermore, oval-
bumin (OVA)-expressing tumor regressed in mice immunized with
liposomal OVA peptide [18]. In addition, liposomal peptide has the
ability to induce long-lived memory CTLs in mice. The above ﬁnd-
ings on the basis of the use of a viral ormodel antigen indicated that
liposome-coupled TAA-derived CTL epitope peptide may be
promising for tumor treatment. To date, however, the therapeutic
potential of such vaccine has not been clariﬁed.
In this study, we chemically coupled GPC3-derived epitope
peptide (pGPC3) to liposome surfaces (pGPC3-liposome), and
investigated its ability to induce peptide-speciﬁc CTLs and its
antitumor effect in vivo.
2. Materials and methods
2.1. Mice
C57BL/6 (B6) mice were purchased from Charles River Labora-
tories Japan (Kanagawa, Japan). HLA-A*02:01 transgenic mice (A2-
Tg mice)dH-2Db b2m double knockout mice transformed with
human b2m-HLA-A2.1 (a1a2)-H-2Db (a3 transmembrane cyto-
plasmic) monochain constructdwere generated in the Department
SIDA-Retrovirus, Unite d' Immunite Cellulaire Antivirale, Institut
Pasteur, France and kindly provided by Dr. F.A. Lemonnier [19,20].
The mice were maintained under the institutional guidelines set by
the Animal Research Committee of the National Cancer Center
Hospital East, Japan. The animals were housed in speciﬁc pathogen-
free (SPF) conditions with a 12-h light cycle and access to food and
water ad libitum. Six-to ten-week-old mice were used in all
experiments.
2.2. Cell lines
RMA-S is a transporter-associated antigen processing (TAP)-
defective B6 thymoma cell line; this cell cannot present endoge-
nous antigens via MHC class I [21]. RMA-S-HHD is RMA-S trans-
fected with the HLA-A*02:01-Db-b2-microglobulin single chain
gene. RMA-HHD-GPC3 is RMA-HHD transfected with the murine
GPC3 gene. All cells were cultured in RPMI 1640 (Thermo Fisher
Scientiﬁc Inc., Waltham, MA, USA) supplemented with 10% fetal
bovine serum (FBS) (Thermo Fisher Scientiﬁc), penicillin-
streptomycin solution (Thermo Fisher Scientiﬁc), and 2-
mercaptoethanol (2-ME, 50 mM).
2.3. Peptides
Amino acid sequences of HLA-A*02:01-restricted GPC3-derived
CTL epitope peptide (pGPC3(A2)), and H2-Kb- or H2-Db-restricted
murine GPC3-derived CTL epitope peptide (pGPC3(B6)) are as fol-
lows: pGPC3(A2), FVGEFFTDV; pGPC3(B6), AMFKNNYPSL. Syn-
thetic pGPC3(A2) was purchased from the American PeptideCompany Inc. (Sunnyvale, CA, USA) and dissolved in 7% NaHCO3
solution (Otsuka Pharmaceutical Factory Inc., Tokyo, Japan) at
10 mg/mL. Synthetic pGPC3(B6) was purchased from Scrum Inc.
(Tokyo, Japan) and dissolved in dimethyl sulfoxide (DMSO) (Wako
Pure Chemical Industries Ltd., Osaka, Japan) at 10 mg/mL.
2.4. Liposomes
“Oleoyl” liposomes, consisting of dioleoyl phosphatidyl choline,
dioleoyl phosphatidyl ethanolamine, dioleoyl phosphatidyl glyc-
erol acid, and cholesterol in a 4:3:2:7 M ratio, were used in this
study.
2.5. CpG oligodeoxynucleotide
CpG oligodeoxynucleotide (CpG ODN) 5002: (50-TCCAT-
GACGTTCTTGATGTT-30) was synthesized by Hokkaido System Sci-
ence Co., Ltd. (Hokkaido, Japan) and was phosphorothioate-
protected to avoid nuclease-dependent degradation. CpG was dis-
solved in distilled water at a concentration of 4 mg/mL.
2.6. Coupling of GPC3-derived peptides to the liposomes
Peptide-conjugated liposomes were prepared as described
previously [22]. Liposomal peptide density was assessed by quan-
titative amino acid analysis (by Shimadzu Techno-Research Inc.,
Kyoto, Japan).
2.7. Liposomal and IFA-emulsiﬁed peptide vaccination
The liposomal vaccines pGPC3(A2)-liposome and pGPC3(B6)-
liposome were administrated at 1 mg, 10 mg, or 50 mg of peptide
per mouse in the presence of CpG ODN 5002 (5 mg/mouse). IFA-
emulsiﬁed peptide vaccine was administered as an emulsion of
peptide solution (100 mL/mouse) and IFA (100 mL/mouse). Mice
were immunized with two separate intradermal injections at the
base of the tail according to the schedules shown in Figs. 1A, D and
3A.
2.8. Generation of bone marrow-derived dendritic cells (BM-DCs)
BM-DCs were generated as described previously [11]. In brief,
bone marrow cells (2  106) derived from B6 mice were cultured in
RPMI 1640 containing FBS (10%), 2-ME (50 mM), and murine
granulocyte-macrophage colony-stimulating factor (mGM-CSF,
20 ng/mL). After 7 days of culture, ﬂoating cells were collected and
used as BM-DCs.
2.9. In vitro stimulation of splenocytes derived from immunized
mice
Seven days after the last immunization, splenocytes were
collected and CD8þ splenocytes were isolated by positive magnetic
cell sorting with anti-CD8 microbeads (Miltenyi Biotec K.K., Tokyo,
Japan) according to the manufacturer's protocol. CD8þ splenocytes
were cocultured with peptide-pulsed BM-DCs for 7 days and the
antigen-speciﬁc T cell frequency was determined.
2.10. IFN-g enzyme-linked immunospot (ELISpot) assay
The frequency of IFN-g-producing cells was detected using an
ELISpot assay kit (BD Bioscience, San Jose, CA, USA) according to the
manufacturer's protocol.
Fig. 1. Effective induction of GPC3 peptide-speciﬁc CTLs by liposome-coupled pGPC3. (A) Experimental setup for analyzing the induction of pGPC3-speciﬁc CTLs. (B, C) A2-Tg mice
were immunized twice (7-day interval) with pGPC3(A2) coupled to liposomes containing CpG ODN (B) or IFA-emulsiﬁed pGPC3(A2) (C). Seven days after the second immunization,
CD8þ splenocytes were cocultured with RMA-S-HHD cells pre-pulsed with pGPC3(A2) for 20 h and the frequencies of IFN-g-producing cells were evaluated by IFN-g ELISpot assay.
Peptide(þ): RMA-S-HHD pulsed with pGPC3(A2), peptide(): non-pulsed RMA-S-HHD. (D) Experimental setup for analyzing the induction of pGPC3-speciﬁc CTLs. (E, F) B6 mice
were immunized with twice (7-day interval) pGPC3(B6) coupled to liposomes containing CpG ODN (E) or IFA-emulsiﬁed pGPC3(B6) (F). Seven days after the second immunization,
CD8þ splenocytes were stimulated with BM-DCs pre-pulsed with pGPC3(B6). After 7 days, stimulated CD8þ cells were cocultured with RMA-S for 20 h and the frequencies of IFN-g-
producing cells were evaluated by IFN-g ELISpot assay. Peptide(þ): RMA-S pulsed with pGPC3(B6), peptide(): non-pulsed RMA-S.
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At 14 and 7 days before tumor transfer, the mice were immu-
nized with vaccine. At day 0, A2-Tg mice were injected with RMA-
HHD-GPC3 (5.0  105 cells). At day 7 after tumor transfer, the mice
were immunized again. The lengths of the major and minor axes of
the tumor were measured by using a caliper. The tumor area was
calculated according to following formula: (tumor area) ¼ (length
of major tumor axis)  (length of minor tumor axis).
2.12. Statistical analysis
Statistical analyses of the ELISpot assays and the antitumor ef-
fect of the vaccines were performed using a ManneWhitney U or
KruskaleWallis test. Signiﬁcant differences were deﬁned as
*p < 0.05.
3. Results
3.1. Liposome-coupled pGPC3 efﬁciently stimulates peptide-speciﬁc
CTLs in vivo
We previously found that a high dose of pGPC3 (50 mg)
emulsiﬁed with IFA can stimulate priming of pGPC3-speciﬁc CTLsin vivo [10]. To analyze the immunogenic potential of the pGPC3-
liposome vaccine, A2-Tg mice were immunized with pGPC3(A2)-
liposome containing CpG ODN, one of the ligands for toll-like re-
ceptor 9 (TLR9) [23], (pGPC3(A2)-liposome/CpG), and the fre-
quency of pGPC3-speciﬁc CTLs was evaluated by IFN-g ELISpot
assay. Vaccination with pGPC3(A2)-liposome/CpG induced
pGPC3(A2)-speciﬁc CD8þ CTLs at a low dose (1 mg) that was 1/50
the amount of peptide used in conventional IFA-emulsiﬁed
vaccine (Fig. 1B). In contrast, when A2-Tg mice were immunized
with IFA-emulsiﬁed pGPC3(A2) vaccine containing an equal dose
of pGPC3 (1 mg), no pGPC3(A2)-speciﬁc CD8þ CTLs were detected
(Fig. 1C).
Next, B6 mice were immunized with pGPC3(B6)-liposome
containing CpG ODN (pGPC3(B6)-liposome/CpG) or IFA-
emulsiﬁed pGPC3(B6). The results showed that vaccination with
both pGPC3(B6)-liposome/CpG and IFA-emulsiﬁed pGPC3(B6)
induced pGPC3(B6)-speciﬁc CD8þ CTLs at a low (10 mg) or high
(50 mg) dose (Fig. 1E, F, G). However, the frequency of pGPC3(B6)-
speciﬁc CD8þ splenocytes in mice immunized with pGPC3(B6)-
liposome/CpG tended to be higher than that in mice treated with
IFA-emulsiﬁed pGPC3(B6) vaccine (Fig. 1E, F).
The results suggested that pGPC3-liposome elicits peptide-
speciﬁc CTLs in vivo and liposome-coupled peptide vaccine is
more effective than IFA-emulsiﬁed vaccine for CTL induction.
Fig. 2. Coupling of peptides to liposomes is crucial for effective induction of peptide-
speciﬁc CTLs. (A) A2-Tg mice (n ¼ 8) were immunized with pGPC3(A2) liposome
containing CpG as shown in Fig. 1A. CD8þ splenocytes were cocultured with peptide-
pulsed (þ) or non-pulsed () RMA-S-HHD, and the frequencies of IFN-g-producing
cells were evaluated by IFN-g ELISpot assay. pGPC3(A2)-liposome/CpG: pGPC3(A2)
coupled-liposome containing CpG ODN, pGPC3(A2): mixture of pGPC3(A2), liposome,
and CpG ODN, liposome/CpG: mixture of liposome and CpG ODN. (B) B6 mice (n ¼ 8)
were immunized with pGPC3(B6) liposome containing CpG as shown in Fig. 1A. CD8þ
splenocytes were cocultured with peptide-pulsed (þ) or non-pulsed () RMA-S, and
the frequencies of IFN-g-producing cells were evaluated. (C) B6 mice were immunized
with pGPC3(B6)-liposome containing CpG or mixture of pGPC3(B6), liposome, and CpG
as indicated in Fig. 1A. CD8þ splenocytes were cocultured with pGPC3(B6)-pulsed
RMA-S, and the frequencies of IFN-g-producing cells were evaluated. (B, C)
pGPC3(B6)-liposome/CpG: pGPC3(B6) coupled-liposome containing CpG ODN,
pGPC3(B6): mixture of pGPC3(B6), liposome, and CpG ODN, liposome/CpG: mixture of
liposome and CpG ODN. *p < 0.05.
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induction
Next, we investigated whether coupling of the peptides to li-
posomes is required for effective CTL induction. A2-Tg mice were
immunized with a mixture of pGPC3(A2)/liposome/CpG ODN
(uncoupled pGPC3(A2) liposome vaccine) or with pGPC3(A2)-
liposome/CpG (coupled pGPC3(A2) liposome vaccine), and the
frequencies of pGPC3-speciﬁc CTLs were evaluated. The coupled
pGPC3(A2) liposome vaccine effectively induced pGPC3(A2)-
speciﬁc CD8þ CTLs in the spleen (Fig. 2A). In contrast, when the
mice were immunized with uncoupled pGPC3(A2) liposome vac-
cine, pGPC3-speciﬁc CD8þ CTLs were not detected (Fig. 2A).
Next, B6 mice were immunized with a mixture of pGPC3 (B6)/
liposome/CpG ODN (uncoupled pGPC3(B6) liposome vaccine) or
with pGPC3(B6)-liposome/CpG (coupled pGPC3(B6) liposome
vaccine). Vaccination with both uncoupled and coupled pGPC3(B6)
liposome vaccine induced pGPC3(B6)-speciﬁc CD8þ CTLs (Fig. 2B).
However, the frequency of pGPC3(B6)-speciﬁc CD8þ CTLs in mice
injected with the coupled vaccine was higher than that in mice that
had received the uncoupled vaccine (Fig. 2C).
These results suggested that the coupling of the peptides to li-
posomes is essential for effective induction of pGPC3-speciﬁc CTLs
in vivo.
3.3. Liposome-coupled pGPC3 inhibits GPC3-expressing tumor
growth in vivo
To investigate the antitumor effect of the pGPC3-liposome
vaccine, A2-tg mice were immunized and subcutaneously injec-
ted with RMA-HHD-GPC3 cells (expressing murine GPC3) accord-
ing to the schedule in Fig. 3A. The antitumor effect was evaluated by
measuring tumor growth. The tumor area in mice immunized with
pGPC3(A2)-liposome/CpG was smaller than in the other groups,
and complete regression was observed in one of the mice treated
with pGPC3(A2)-liposome/CpG (Fig. 3B,C). These results suggested
that pGPC3-liposome vaccine exerts antitumor effect in GPC3-
expressing tumor model.
4. Discussion
Multiple clinical trials have used IFA-emulsiﬁed peptide vacci-
nation to induce TAA-speciﬁc T cell responses in cancer patients.
Recently, it has been reported that IFA-emulsiﬁed peptide vacci-
nation causes CTL hypo-responsiveness in a murine model [15].
Therefore, new vaccines without IFA are desired.
Liposomal vaccines have been prepared by entrapment of anti-
gens within the aqueous lumen of liposomes, which, besides their
role as antigen carrier, are known to act as adjuvants. In a pre-
liminary study, we tried to encapsulate pGPC3 within liposomes;
however, no encapsulated pGPC3 could be detected (data not
shown), suggesting that the peptide might be too short to be
retained within the liposomes. Therefore, we aimed to develop an
alternative preparation method for the liposomal peptide vaccine.
We previously reported coupling of antigens and short peptides to
the surfaces of liposomes as an alternative technique for vaccine
preparation [17,22,24]. Furthermore, we showed that liposome-
coupled peptides derived from the model antigen OVA inhibited
the growth of OVA-expressing tumor [18]. However, the immuno-
logical effects of true TAA peptide-coupled liposome have not been
investigated to date.
We showed that pGPC3-speciﬁc CTLs were effectively induced
in mice immunized with pGPC3-liposome vaccine. Moreover, in-
ductionwas obtainedwith a lower dose of peptide than that used in
conventional IFA-emulsiﬁed peptide vaccine (Fig. 1). CpG ODN acts
Fig. 3. Vaccination with liposome-coupled pGPC3 inhibits GPC3-expressing tumor growth. (A) Experimental setup for analyzing the in vivo antitumor effect. At days 14 and 7,
pGPC3 coupled to liposomes containing CpG ODN or a mixture of pGPC3(A2), liposome, and CpG ODN was administrated. RNA-HHD-GPC3 cells were injected at day 0. After 7 days,
vaccination was repeated. (B, C) Individual (B) and average (C) tumor areas. Tumor area was calculated according to following formula: (tumor area) ¼ (length of major tumor
axis)  (length of minor tumor axis).
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epitope peptide by activating antigen-presenting cells, thereby
promoting cell-mediated immune responses (Th1 responses) [25].
Indeed, we observed that pGPC3-liposome vaccination with CpG
ODN elicited peptide-speciﬁc CTLs in vivomore effectively than that
without CpG ODN (data not shown, Fig. 1). However, despite the
presence of CpGODN, the uncoupled pGPC3/liposome/CpGmixture
elicited pGPC3-speciﬁc CTLs less effectively than the coupled
pGPC3-liposome/CpG vaccine (Fig. 2). These observations sug-
gested that coupling of the peptides to liposomes is essential for
effective induction of pGPC3-speciﬁc CTLs.
Finally, we demonstrated that liposome-coupled pGPC3 vacci-
nation inhibited GPC3-expressing tumor growth in vivo (Fig. 3). It
has been recently reported that a “long” peptide vaccine containingboth MHC class I and class II epitopes leads to more effective tumor
rejection than a “short” peptide containing either an MHC class I or
an MHC class II-related epitope [26,27]. It is conceivable that
liposome-coupled GPC3-derived long peptide vaccine containing
both MHC class I and class II-restricted epitopes has the potential
for more effective antitumor effects.
In conclusion, we developed a surface-coupled liposomal pGPC3
vaccine and showed that intradermal administration of this vaccine
effectively elicits pGPC3-speciﬁc CTLs and exerts antitumor effects
against GPC3-expressing tumor in vivo in mice. Therefore,
liposome-coupled pGPC3may become a new therapeutic option for
HCC as an alternative to IFA-based vaccines and, more generally,
surface-coupled TAA peptides may have promising potential in
cancer therapy.
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